Virusno vektorsko cepivo (Slovenian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Virusno vektorsko cepivo" in Slovenian language version.

refsWebsite

Global rank Slovenian rank

10nih.gov

4^th place

8^th place

6doi.org

2^nd place

5^th place

6clinicaltrials.gov

5,225^th place

4,764^th place

3web.archive.org

1^st place

2^nd place

3fda.gov

447^th place

409^th place

3europa.eu

68^th place

28^th place

2cdc.gov

218^th place

83^rd place

1medicalnewstoday.com

3,011^th place

965^th place

1termania.net

low place

34^th place

1nijz.si

low place

229^th place

1clinicaltrialsregister.eu

low place

1nytimes.com

7^th place

37^th place

1statnews.com

8,771^st place

7,096^th place

1jnj.com

low place

cdc.gov

CDC (13. april 2021). »Understanding Viral Vector COVID-19 Vaccines«. Centers for Disease Control and Prevention (v ameriški angleščini). Pridobljeno 16. maja 2021.
»Understanding and Explaining Viral Vector COVID-19 Vaccines«. U.S. Centers for Disease Control and Prevention. 25. februar 2021. Pridobljeno 2. aprila 2021.

clinicaltrials.gov

University of Oxford (19. april 2021). »A Phase 2/3 Study to Determine the Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19«. {{navedi revijo}}: Sklic magazine potrebuje|magazine= (pomoč)
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation (11. avgust 2020). »An Open Study of the Safety, Tolerability and Immunogenicity of the Drug "Gam-COVID-Vac" a Solution for Intramuscular Injection With the Participation of Healthy Volunteers«. {{navedi revijo}}: Sklic magazine potrebuje|magazine= (pomoč)
Janssen Vaccines & Prevention B.V. (7. april 2021). »A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26COVS1 in Adults Aged 18 to 55 Years Inclusive and Adults Aged 65 Years and Older«. {{navedi revijo}}: Sklic magazine potrebuje|magazine= (pomoč)
Janssen Vaccines & Prevention B.V. (7. april 2021). »A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older«. {{navedi revijo}}: Sklic magazine potrebuje|magazine= (pomoč)
CanSino Biologics Inc. (25. november 2020). »A Randomized, Double-blind, Placebo -Controlled Phase IIb Clinical Trial to Evaluate the Safety and Immunogenicity of Ad5-nCoV in Person 6 Years of Age and Older and Those Who Have Previously Been Vaccinated With Ad5-EBOV«. {{navedi revijo}}: Sklic magazine potrebuje|magazine= (pomoč)
Crucell Holland BV (13. april 2017). »A Phase 1, First-in-Human Study to Evaluate the Safety, Tolerability and Immunogenicity of Heterologous Prime-Boost Regimens Using MVA-BN®-Filo and Ad26.ZEBOV Administered in Different Sequences and Schedules in Healthy Adults«. {{navedi revijo}}: Sklic magazine potrebuje|magazine= (pomoč)

clinicaltrialsregister.eu

»A Phase 2/3 study to determine the efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19«. EU Clinical Trials Register. European Union. 21. april 2020. EudraCT 2020-001228-32. Arhivirano iz spletišča dne 5. oktobra 2020. Pridobljeno 3. avgusta 2020.

doi.org

Ura T, Okuda K, Shimada M (Julij 2014). »Developments in Viral Vector-Based Vaccines«. Vaccines. 2 (3): 624–41. doi:10.3390/vaccines2030624. PMC 4494222. PMID 26344749.
Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, in sod. (Avgust 2020). »Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial«. Lancet. 396 (10249): 479–88. doi:10.1016/S0140-6736(20)31605-6. PMC 7836858. PMID 32702299.
Marzi A, Ebihara H, Callison J, Groseth A, Williams KJ, Geisbert TW, Feldmann H (november 2011). »Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy«. The Journal of Infectious Diseases. 204 Suppl 3 (suppl 3): S1066–74. doi:10.1093/infdis/jir348. PMID 21987743.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Martínez-Romero C, García-Sastre A (november 2015). »Against the clock towards new Ebola virus therapies«. Virus Research. 209: 4–10. doi:10.1016/j.virusres.2015.05.025. PMID 26057711.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Choi WY, Hong KJ, Hong JE, Lee WJ (Januar 2015). »Progress of vaccine and drug development for Ebola preparedness«. Clinical and Experimental Vaccine Research. 4 (1): 11–16. doi:10.7774/cevr.2015.4.1.11. PMC 4313103. PMID 25648233.
Regules JA, Beigel JH, Paolino KM, Voell J, Castellano AR, Hu Z, in sod. (Januar 2017). »A Recombinant Vesicular Stomatitis Virus Ebola Vaccine«. The New England Journal of Medicine. 376 (4): 330–41. doi:10.1056/NEJMoa1414216. PMC 5408576. PMID 25830322.

europa.eu

ema.europa.eu

»Ervebo EPAR«. Evropska agencija za zdravila (EMA). 12. december 2019. Pridobljeno 1. julija 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
»Zabdeno EPAR«. Evropska agencija za zdravila (EMA). 26. maj 2020. Pridobljeno 23. julija 2020.
»Mvabea EPAR«. Evropska agencija za zdravila (EMA). 26. maj 2020. Pridobljeno 23. julija 2020.

fda.gov

FDA Briefing Document Janssen Ad26.COV2.S Vaccine for the Prevention of COVID-19 (PDF) (poročilo). U.S. Food and Drug Administration (FDA). Laični povzetek. {{navedi report}}: Sklic uporablja opuščeni parameter |lay-url= (pomoč)
»First FDA-approved vaccine for the prevention of Ebola virus disease, marking a critical milestone in public health preparedness and response«. U.S. Food and Drug Administration (FDA). 19. december 2019. Arhivirano iz spletišča dne 20. decembra 2019. Pridobljeno 19. decembra 2019. Članek vsebuje besedilo iz tega vira, ki je v javni domeni.
»Ervebo«. U.S. Food and Drug Administration (FDA). 19. december 2019. Pridobljeno 1. julija 2020.

jnj.com

»Johnson & Johnson Announces European Commission Approval for Janssen's Preventive Ebola Vaccine« (tiskovna objava). Johnson & Johnson. 1. julij 2020. Pridobljeno 16. julija 2020.

medicalnewstoday.com

»COVID-19: How does the Oxford-AstraZeneca viral vector vaccine work?«. www.medicalnewstoday.com (v angleščini). 15. januar 2021. Pridobljeno 16. maja 2021.

nih.gov

pubmed.ncbi.nlm.nih.gov

Ura T, Okuda K, Shimada M (Julij 2014). »Developments in Viral Vector-Based Vaccines«. Vaccines. 2 (3): 624–41. doi:10.3390/vaccines2030624. PMC 4494222. PMID 26344749.
Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, in sod. (Avgust 2020). »Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial«. Lancet. 396 (10249): 479–88. doi:10.1016/S0140-6736(20)31605-6. PMC 7836858. PMID 32702299.
Marzi A, Ebihara H, Callison J, Groseth A, Williams KJ, Geisbert TW, Feldmann H (november 2011). »Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy«. The Journal of Infectious Diseases. 204 Suppl 3 (suppl 3): S1066–74. doi:10.1093/infdis/jir348. PMID 21987743.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Martínez-Romero C, García-Sastre A (november 2015). »Against the clock towards new Ebola virus therapies«. Virus Research. 209: 4–10. doi:10.1016/j.virusres.2015.05.025. PMID 26057711.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Choi WY, Hong KJ, Hong JE, Lee WJ (Januar 2015). »Progress of vaccine and drug development for Ebola preparedness«. Clinical and Experimental Vaccine Research. 4 (1): 11–16. doi:10.7774/cevr.2015.4.1.11. PMC 4313103. PMID 25648233.
Regules JA, Beigel JH, Paolino KM, Voell J, Castellano AR, Hu Z, in sod. (Januar 2017). »A Recombinant Vesicular Stomatitis Virus Ebola Vaccine«. The New England Journal of Medicine. 376 (4): 330–41. doi:10.1056/NEJMoa1414216. PMC 5408576. PMID 25830322.

ncbi.nlm.nih.gov

Ura T, Okuda K, Shimada M (Julij 2014). »Developments in Viral Vector-Based Vaccines«. Vaccines. 2 (3): 624–41. doi:10.3390/vaccines2030624. PMC 4494222. PMID 26344749.
Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, in sod. (Avgust 2020). »Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial«. Lancet. 396 (10249): 479–88. doi:10.1016/S0140-6736(20)31605-6. PMC 7836858. PMID 32702299.
Choi WY, Hong KJ, Hong JE, Lee WJ (Januar 2015). »Progress of vaccine and drug development for Ebola preparedness«. Clinical and Experimental Vaccine Research. 4 (1): 11–16. doi:10.7774/cevr.2015.4.1.11. PMC 4313103. PMID 25648233.
Regules JA, Beigel JH, Paolino KM, Voell J, Castellano AR, Hu Z, in sod. (Januar 2017). »A Recombinant Vesicular Stomatitis Virus Ebola Vaccine«. The New England Journal of Medicine. 376 (4): 330–41. doi:10.1056/NEJMoa1414216. PMC 5408576. PMID 25830322.

nijz.si

»Cepljenje proti covidu-19 - za strokovno javnost | www.nijz.si«. www.nijz.si. Arhivirano iz prvotnega spletišča dne 16. maja 2021. Pridobljeno 16. maja 2021.

nytimes.com

Corum J, Carl Z (8. januar 2021). »How Gamaleya's Vaccine Works«. The New York Times. Pridobljeno 27. januarja 2021.

statnews.com

FDA Briefing Document Janssen Ad26.COV2.S Vaccine for the Prevention of COVID-19 (PDF) (poročilo). U.S. Food and Drug Administration (FDA). Laični povzetek. {{navedi report}}: Sklic uporablja opuščeni parameter |lay-url= (pomoč)

termania.net

»Termania - Slovenski medicinski slovar - tropízem«. www.termania.net. Pridobljeno 16. maja 2021.

web.archive.org

»Cepljenje proti covidu-19 - za strokovno javnost | www.nijz.si«. www.nijz.si. Arhivirano iz prvotnega spletišča dne 16. maja 2021. Pridobljeno 16. maja 2021.
»A Phase 2/3 study to determine the efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19«. EU Clinical Trials Register. European Union. 21. april 2020. EudraCT 2020-001228-32. Arhivirano iz spletišča dne 5. oktobra 2020. Pridobljeno 3. avgusta 2020.
»First FDA-approved vaccine for the prevention of Ebola virus disease, marking a critical milestone in public health preparedness and response«. U.S. Food and Drug Administration (FDA). 19. december 2019. Arhivirano iz spletišča dne 20. decembra 2019. Pridobljeno 19. decembra 2019. Članek vsebuje besedilo iz tega vira, ki je v javni domeni.